Haile, Simon
Corbett, Richard D.
MacLeod, Tina
Bilobram, Steve
Smailus, Duane
Tsao, Philip
Kirk, Heather
McDonald, Helen
Pandoh, Pawan
Bala, Miruna
Hirst, Martin
Miller, Diane
Moore, Richard A.
Mungall, Andrew J.
Schein, Jacquie
Coope, Robin J.
Ma, Yussanne
Zhao, Yongjun
Holt, Rob A.
Jones, Steven J.
Marra, Marco A.
Funding for this research was provided by:
Canadian Institutes of Health Research (FDN-143288)
British Columbia Cancer Foundation
Genome Canada (CA)/Genome BC
Genome Canada (CA)/Genome BC
Genome Canada
Western Economic Diversification Canada
Canada Foundation for Innovation
National Cancer Institute (HHSN261200800001E)
Article History
Received: 25 October 2016
Accepted: 22 June 2017
First Online: 5 July 2017
Ethics approval and consent to participate
: Some of the patient samples used in this study are part of the BC Cancer Agency’s Personalized Oncogenomics project [CitationRef removed], which was approved by the University of British Columbia Research Ethics Committee (REB# H12–00137). Sample use was according to the written consent by each patient. Patient identity was made anonymous and sequence data and analyses thereafter were maintained within a secure computing environment.Human promyelocytic Leukemia cell line (HL60) was purchased from Cedarlane Laboratories LTD.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.